p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies

Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway

(2011) Thorsten Zenz et al.   CELL CYCLE

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia

(2011) Teresa Palomero et al.   CELL CYCLE

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis

(2011) Dale Bixby et al.   CELL CYCLE

The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells

(2011) Angelina V. Vaseva et al.   CELL CYCLE

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols

(2010) L Zuurbier et al.   LEUKEMIA

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

(2010) E Clappier et al.   LEUKEMIA

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function

(2010) C Kox et al.   LEUKEMIA

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

(2010) Taimur Sher et al.   LEUKEMIA & LYMPHOMA

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Therapeutic targeting of p53 by small molecules

(2010) Galina Selivanova   SEMINARS IN CANCER BIOLOGY

2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

(2009) A. J. Steele et al.   BLOOD

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model

(2009) K. Cullion et al.   BLOOD

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

(2009) P. Secchiero et al.   BLOOD

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

(2009) C. S. Tam et al.   BLOOD

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

(2009) R. Lapalombella et al.   BLOOD

Modes of p53 Regulation

(2009) Jan-Philipp Kruse et al.   CELL

Notch Signaling: The Core Pathway and Its Posttranslational Regulation

(2009) Mark E. Fortini   DEVELOPMENTAL CELL

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

(2009) K D Mason et al.   LEUKEMIA

NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia

(2009) P J Real et al.   LEUKEMIA

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

(2008) A. J. Steele et al.   BLOOD

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells

(2008) E. Rosati et al.   BLOOD

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

(2008) L. Paoluzzi et al.   BLOOD

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD

p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts

(2008) E. B. Dinca et al.   CANCER RESEARCH

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

The dark side of a tumor suppressor: anti-apoptotic p53

(2008) R U Jänicke et al.   CELL DEATH AND DIFFERENTIATION

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

(2008) O G Best et al.   LEUKEMIA

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

(2008) O G Best et al.   LEUKEMIA

γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia

(2008) Pedro J Real et al.   NATURE MEDICINE

Is NF-κB a good target for cancer therapy? Hopes and pitfalls

(2008) Véronique Baud et al.   NATURE REVIEWS DRUG DISCOVERY

The p53 family and programmed cell death

(2008) E C Pietsch et al.   ONCOGENE

It's T-ALL about Notch

(2008) R M Demarest et al.   ONCOGENE

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY